Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.
The aim of this study was to evaluate the variation in serum alkaline DNase activity (SADA) as a means of therapeutic monitoring in patients with head and neck cancer. Blood samples from 40 patients were collected before, during, and some weeks up to months after therapy. A decrease in SADA during treatment was usually associated with a primary clinical response, while no decrease indicated non-response to therapy. In patients with complete tumor regression the initial decrease of SADA was usually followed by an increase exceeding the initial level. A similar increase was not observed in patients with tumor progression.
Economidou-Karaoglou
A
A
Toxicologic and Cancerologic Biochemistry Unit, Medical Faculty, University of Louvain, Brussels, Belgium.
Opsomer
M
M
Lans
M
M
Taper
H S
HS
Deckers
C
C
Roberfroid
M B
MB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003850:Deoxyribonuclease I / Q000097:blood*; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011237:Predictive Value of Tests
D014408:Biomarkers, Tumor; D001761:Bleomycin; D003850:Deoxyribonuclease I; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate